Zevra Therapeutics (NASDAQ:ZVRA) Sets New 1-Year High – Should You Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $14.30 and last traded at $14.2950, with a volume of 267986 shares changing hands. The stock had previously closed at $14.01.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZVRA. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, June 9th. Guggenheim upped their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Canaccord Genuity Group increased their price objective on Zevra Therapeutics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.29.

Zevra Therapeutics Trading Up 2.9%

The business’s fifty day simple moving average is $11.41 and its 200 day simple moving average is $9.85. The stock has a market cap of $852.44 million, a price-to-earnings ratio of 7.25 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The company had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. As a group, research analysts anticipate that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZVRA. Quantinno Capital Management LP grew its position in shares of Zevra Therapeutics by 114.1% during the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after buying an additional 17,065 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Zevra Therapeutics by 259.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock valued at $5,168,000 after acquiring an additional 400,336 shares during the period. AIGH Capital Management LLC acquired a new stake in shares of Zevra Therapeutics in the 1st quarter valued at approximately $11,184,000. Simplify Asset Management Inc. boosted its stake in Zevra Therapeutics by 137.5% during the 1st quarter. Simplify Asset Management Inc. now owns 100,630 shares of the company’s stock worth $938,000 after acquiring an additional 58,265 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Zevra Therapeutics by 16.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock worth $2,207,000 after acquiring an additional 33,951 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.